|

An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors

RECRUITINGSponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Actively Recruiting
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
Started2021-01-01
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This retrospective + prospective, non-interventional study aims to develop and evaluate artificial intelligence methods for the detection, pathological subtyping, and histological grading of renal tumors using magnetic resonance imaging (MRI). Approximately 900 adult patients with available preoperative renal MRI examinations and postoperative pathological results will be included. The pathological findings will be used as the reference standard for model development and evaluation. In addition to MRI data, selected demographic, clinical, and laboratory information may be incorporated to improve model performance. The study will not change participants' diagnosis, treatment, or follow-up, and no additional examinations or interventions will be required. All study data will be de-identified before analysis. The ultimate goal is to develop an MRI-based intelligent diagnostic approach that may assist clinicians in the preoperative assessment and individualized management of patients with renal tumors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients aged 18 years or older.
* Patients diagnosed with a renal tumor.
* Availability of preoperative renal magnetic resonance imaging examinations.
* Availability of a corresponding pathological diagnosis, including pathological subtype and, where applicable, histological grade.
* Magnetic resonance images that can be successfully retrieved and are of - - sufficient quality for image analysis.

Exclusion Criteria:

* Absence of renal magnetic resonance imaging data.
* Absence of a corresponding pathological diagnosis or insufficient pathological subtype or grading information.
* Magnetic resonance images that cannot be retrieved, opened, or read.
* Poor image quality that precludes reliable image annotation or artificial intelligence analysis.

Conditions3

CancerKidney NeoplasmRenal Tumor

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.